• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".

作者信息

Hughes Amy, Clarson Jade, Gargett Tessa, Yu Wenbo, Brown Michael P, Lopez Angel F, Hughes Timothy P, Yong Agnes S M

机构信息

Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia; The University of Adelaide, School of Medicine, Adelaide, South Australia, Australia.

Department of Haematology, SA Pathology, Adelaide, South Australia, Australia; Cancer Theme, South Australia Health and Medical Research Institute (SAHMRI), Adelaide, South Australia, Australia.

出版信息

Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9.

DOI:10.1016/j.leukres.2017.01.009
PMID:28129558
Abstract
摘要

相似文献

1
Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study".关于“KB004，一种靶向受体酪氨酸激酶EphA3的首创单克隆抗体，用于晚期血液系统恶性肿瘤患者：1期研究结果”的评论
Leuk Res. 2017 Apr;55:55-57. doi: 10.1016/j.leukres.2017.01.009. Epub 2017 Jan 9.
2
KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.KB004，一种靶向受体酪氨酸激酶EphA3的首创单克隆抗体，用于晚期血液系统恶性肿瘤患者：1期研究结果。
Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28.
3
Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].
Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30.
4
Copy number variations of EphA3 are associated with multiple types of hematologic malignancies.EphA3 的拷贝数变异与多种类型的血液系统恶性肿瘤有关。
Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):50-3. doi: 10.3816/CLML.2011.n.006.
5
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme.EphA3 维持肿瘤发生能力，是多形性胶质母细胞瘤的治疗靶点。
Cancer Cell. 2013 Feb 11;23(2):238-48. doi: 10.1016/j.ccr.2013.01.007.
6
Concurrent binding of anti-EphA3 antibody and ephrin-A5 amplifies EphA3 signaling and downstream responses: potential as EphA3-specific tumor-targeting reagents.抗EphA3抗体与ephrin-A5的同时结合增强EphA3信号传导及下游反应：作为EphA3特异性肿瘤靶向试剂的潜力。
Cancer Res. 2005 Aug 1;65(15):6745-54. doi: 10.1158/0008-5472.CAN-05-0758.
7
Tyrosine kinases as targets for cancer therapy.酪氨酸激酶作为癌症治疗的靶点。
N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.
8
Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment.靶向 EphA3 可通过破坏肿瘤基质微环境抑制肿瘤生长。
Cancer Res. 2014 Aug 15;74(16):4470-81. doi: 10.1158/0008-5472.CAN-14-0218.
9
Epha3 acts as proangiogenic factor in multiple myeloma.Epha3在多发性骨髓瘤中作为促血管生成因子发挥作用。
Oncotarget. 2017 May 23;8(21):34298-34309. doi: 10.18632/oncotarget.16100.
10
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells.EphA3 靶向减少多发性骨髓瘤细胞的体外黏附和侵袭以及体内生长和血管生成。
Cell Oncol (Dordr). 2017 Oct;40(5):483-496. doi: 10.1007/s13402-017-0338-4. Epub 2017 Jul 18.

引用本文的文献

1
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids.靶向Eph-Ephrin系统的蛋白质-蛋白质相互作用抑制剂：聚焦于胆汁酸的氨基酸缀合物
Pharmaceuticals (Basel). 2022 Jan 24;15(2):137. doi: 10.3390/ph15020137.